172 related articles for article (PubMed ID: 25380887)
1. YKL-40, a marker of cardiovascular disease and endothelial dysfunction, in kidney transplant recipients.
Malyszko J; Koc-Zorawska E; Malyszko J
Transplant Proc; 2014 Oct; 46(8):2651-3. PubMed ID: 25380887
[TBL] [Abstract][Full Text] [Related]
2. YKL-40, a novel marker of cardiovascular complications, is related to kidney function in heart transplant recipients.
Przybyłowski P; Janik L; Wasilewski G; Nowak E; Koźlik P; Małyszko J
Transplant Proc; 2014 Oct; 46(8):2860-3. PubMed ID: 25380936
[TBL] [Abstract][Full Text] [Related]
3. Correlation between serum YKL-40 (chitinase-3-like protein 1) level and proteinuria in renal transplant recipients.
Tatar E; Gungor O; Celtik A; Sisman AR; Yaprak M; Asci G; Ozkahya M; Toz H
Ann Transplant; 2013 Mar; 18():95-100. PubMed ID: 23792508
[TBL] [Abstract][Full Text] [Related]
4. Endothelial function and novel adhesion molecule CD44 in kidney allograft recipients.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Transplant Proc; 2008 Dec; 40(10):3470-3. PubMed ID: 19100415
[TBL] [Abstract][Full Text] [Related]
5. Renalase, kidney function, and markers of endothelial dysfunction in renal transplant recipients.
Zbroch E; Małyszko J; Małyszko J; Koc-Żórawska E; Myśliwiec M
Pol Arch Med Wewn; 2012; 122(1-2):40-4. PubMed ID: 22237745
[TBL] [Abstract][Full Text] [Related]
6. Novel inflammatory marker in dialysis patients: YKL-40.
Okyay GU; Er RE; Tekbudak MY; Paşaoğlu Ö; Inal S; Öneç K; Paşaoğlu H; Altok K; Derici Ü; Erten Y
Ther Apher Dial; 2013 Apr; 17(2):193-201. PubMed ID: 23551676
[TBL] [Abstract][Full Text] [Related]
7. Possible relations between thyroid function, endothelium, and kidney and liver function in kidney allograft recipients.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Transplant Proc; 2006 Dec; 38(10):3509-13. PubMed ID: 17175317
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients.
Malyszko J; Malyszko JS; Bachorzewska-Gajewska H; Poniatowski B; Dobrzycki S; Mysliwiec M
Transplant Proc; 2009; 41(1):158-61. PubMed ID: 19249502
[TBL] [Abstract][Full Text] [Related]
9. Resistin, a new adipokine, is related to inflammation and renal function in kidney allograft recipients.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Transplant Proc; 2006 Dec; 38(10):3434-6. PubMed ID: 17175295
[TBL] [Abstract][Full Text] [Related]
10. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure.
Harutyunyan M; Christiansen M; Johansen JS; Køber L; Torp-Petersen C; Kastrup J
Immunobiology; 2012 Jun; 217(6):652-6. PubMed ID: 22209156
[TBL] [Abstract][Full Text] [Related]
11. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial.
Harutyunyan M; Gøtze JP; Winkel P; Johansen JS; Hansen JF; Jensen GB; Hilden J; Kjøller E; Kolmos HJ; Gluud C; Kastrup J
Immunobiology; 2013 Jul; 218(7):945-51. PubMed ID: 23294528
[TBL] [Abstract][Full Text] [Related]
12. Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis?
Erfan G; Guzel S; Alpsoy S; Rifaioglu EN; Kaya S; Kucukyalcın V; Topcu B; Kulac M
Mol Cell Biochem; 2015 Feb; 400(1-2):207-12. PubMed ID: 25421412
[TBL] [Abstract][Full Text] [Related]
13. Elevated circulating levels of the serum acute-phase protein YKL-40 (chitinase 3-like protein 1) are a marker of obesity and insulin resistance in prepubertal children.
Kyrgios I; Galli-Tsinopoulou A; Stylianou C; Papakonstantinou E; Arvanitidou M; Haidich AB
Metabolism; 2012 Apr; 61(4):562-8. PubMed ID: 22036069
[TBL] [Abstract][Full Text] [Related]
14. YKL-40--an emerging biomarker in cardiovascular disease and diabetes.
Rathcke CN; Vestergaard H
Cardiovasc Diabetol; 2009 Nov; 8():61. PubMed ID: 19930630
[TBL] [Abstract][Full Text] [Related]
15. Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients.
Malyszko J; Malyszko JS; Mysliwiec M
Transplant Proc; 2009; 41(1):150-3. PubMed ID: 19249500
[TBL] [Abstract][Full Text] [Related]
16. Relationship of YKL-40 and adiponectin and subclinical atherosclerosis in asymptomatic patients with type 1 diabetes mellitus from a European Mediterranean population.
Aguilera E; Serra-Planas E; Granada ML; Pellitero S; Reverter JL; Alonso N; Soldevila B; Mauricio D; Puig-Domingo M
Cardiovasc Diabetol; 2015 Sep; 14():121. PubMed ID: 26382922
[TBL] [Abstract][Full Text] [Related]
17. [Effects of Guizhi Fuling Decoction on YKL-40 and hs-CRP of patients with non-ST segment elevation acute coronary syndrome].
Pei Q; Sang WF; Zhao XD
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Feb; 33(2):186-90. PubMed ID: 23646472
[TBL] [Abstract][Full Text] [Related]
18. Markers of endothelial cell activation/injury: CD146 and thrombomodulin are related to adiponectin in kidney allograft recipients.
Małyszko J; Małyszko JS; Brzosko S; Wołczynski S; Myśliwiec M
Am J Nephrol; 2005; 25(3):203-10. PubMed ID: 15897668
[TBL] [Abstract][Full Text] [Related]
19. Increased YKL-40 levels in patients with isolated coronary artery ectasia: an observational study.
Erdoğan T; Kocaman SA; Çetin M; Durakoğlugil ME; Kırbaş A; Canga A; Yılmaz A; Doğan S; Çiçek Y
Anadolu Kardiyol Derg; 2013 Aug; 13(5):465-70. PubMed ID: 23728225
[TBL] [Abstract][Full Text] [Related]
20. Increased plasma YKL-40/chitinase-3-like-protein-1 is associated with endothelial dysfunction in obstructive sleep apnea.
Jafari B; Elias JA; Mohsenin V
PLoS One; 2014; 9(5):e98629. PubMed ID: 24878721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
